#1 Clinical Trials Search in Europe

Hhalpc

HepaStem, a cell-based therapy containing HHALPC (Human Allogeneic Liver-Derived Progenitor Cells), is being investigated in clinical trials for various liver disorders. These trials aim to assess the long-term safety and potential efficacy of HepaStem in patients with conditions such as urea cycle disorders, Crigler-Najjar syndrome, fibroinflammatory liver diseases, and acute-on-chronic liver failure (ACLF). The studies involve monitoring patients who have received HepaStem infusions and evaluating its effects on survival and liver function improvement.

Table of Contents

What is HepaStem?

HepaStem, also known as HHALPC (Human Allogeneic Liver-Derived Progenitor Cells), is an innovative medical treatment being developed for various liver disorders[1]. It is classified as an Advanced Therapy Investigational Medicinal Product, which means it’s a cutting-edge treatment that uses cells or genes to treat diseases[2].

HepaStem is a cell suspension for injection, containing liver cells derived from human donors (allogeneic means the cells come from a donor, not the patient themselves)[1]. These cells are specially prepared to help repair and regenerate damaged liver tissue.

Medical Conditions Treated

HepaStem is being studied for the treatment of several liver-related conditions, including:

  • Urea Cycle Disorders (UCD): These are genetic disorders that affect how the body removes nitrogen from the blood[1].
  • Crigler-Najjar Syndrome (CN): A rare disorder that affects how the liver processes bilirubin, a yellow substance produced when red blood cells break down[1].
  • Fibroinflammatory Liver Diseases: Conditions where the liver becomes inflamed and scarred[1].
  • Acute on Chronic Liver Failure (ACLF): A serious condition where a person with long-term liver disease experiences sudden and severe liver failure[2].

How HepaStem Works

HepaStem works by introducing healthy liver progenitor cells into the patient’s body. These cells are capable of developing into mature liver cells and can help repair damaged liver tissue. In conditions like ACLF, HepaStem may help reduce inflammation and improve liver function[2].

Administration and Dosage

HepaStem is administered through intravenous infusion, which means it’s given directly into the bloodstream through a vein[1][2]. The dosage can vary depending on the specific condition being treated and the clinical trial protocol. In one study for ACLF, patients received two infusions of 1.0 million cells per kilogram of body weight, given 7 days apart[2].

Clinical Trials and Research

HepaStem is currently being studied in several clinical trials:

  • A long-term safety study (PROLONGSTEM) is following patients who have received HepaStem in previous clinical trials to assess its long-term effects[1].
  • A Phase IIb study (DHELIVER) is evaluating the safety and effectiveness of HepaStem in patients with Acute on Chronic Liver Failure (ACLF)[2].

These studies aim to determine how well HepaStem works and if it’s safe for patients with various liver conditions.

Safety and Side Effects

As with any medical treatment, researchers are carefully monitoring the safety of HepaStem. The long-term safety study is specifically looking at potential side effects, including:

  • Serious events that may lead to death
  • Need for organ transplantation
  • Development of tumors or unwanted tissue growth
  • Infections or reactivation of dormant infections
  • Any other adverse events that might be related to HepaStem[1]

Patients receiving HepaStem may need to take medications to prevent infusion-related reactions[2].

Future Prospects

HepaStem shows promise as a potential treatment for several serious liver conditions. If the ongoing clinical trials demonstrate that it is safe and effective, it could offer new hope for patients with liver diseases that currently have limited treatment options.

However, it’s important to note that HepaStem is still an investigational treatment. More research is needed to fully understand its benefits and risks before it can be approved for widespread use. Patients interested in HepaStem should discuss current treatment options with their healthcare providers and consider participating in clinical trials if appropriate.

Aspect Details
Drug Name HepaStem (HHALPC)
Trial Types Phase IIb and long-term safety follow-up
Conditions Studied Urea cycle disorders, Crigler-Najjar syndrome, Fibroinflammatory liver diseases, Acute-on-Chronic Liver Failure (ACLF)
Administration Intravenous infusion
Primary Objectives Assess long-term safety, evaluate efficacy on survival and liver function
Key Endpoints Survival at 90 days, liver transplant-free survival, ACLF-free survival, adverse events
Safety Monitoring Adverse events of special interest, including fatal outcomes, organ transplantation, malignancies
Patient Population Adults with various liver disorders, including cirrhotic patients with ACLF

FAQ

  • What is HepaStem? HepaStem is a cell-based therapy containing Human Allogeneic Liver-Derived Progenitor Cells (HHALPC). It is being studied as a potential treatment for various liver disorders.
  • What conditions is HepaStem being tested for? HepaStem is being investigated for conditions such as urea cycle disorders, Crigler-Najjar syndrome, fibroinflammatory liver diseases, and acute-on-chronic liver failure (ACLF).
  • How is HepaStem administered? HepaStem is administered through intravenous infusion. In some trials, patients receive two infusions of 1.0 million cells per kg body weight, given 7 days apart.
  • What are the main goals of the HepaStem clinical trials? The main goals are to assess the long-term safety of HepaStem therapy and to evaluate its efficacy in improving survival and liver function in patients with various liver disorders.
  • Are there any specific safety concerns being monitored? Yes, the trials are monitoring for adverse events of special interest, including fatal outcomes, organ transplantation, development of malignancies, transmission of pathogens, and any adverse events potentially related to HepaStem.

Ongoing Clinical Trials on Hhalpc

  • Long-Term Safety Study of HepaStem for Patients with Urea Cycle Disorders, Crigler-Najjar Syndrome, and Fibroinflammatory Liver Diseases

    Not recruiting

    2 1 1
    Investigated drugs:
    Belgium Bulgaria France Poland Spain

Glossary

  • ACLF (Acute-on-Chronic Liver Failure): A condition where there is a sudden deterioration of liver function in a person with pre-existing chronic liver disease, often accompanied by failure of other organs and a high risk of short-term mortality.
  • HepaStem: A cell-based therapy containing Human Allogeneic Liver-Derived Progenitor Cells (HHALPC), being investigated for various liver disorders.
  • HHALPC: Human Allogeneic Liver-Derived Progenitor Cells, the active component of HepaStem therapy.
  • Urea Cycle Disorders: A group of genetic disorders that affect the body's ability to remove nitrogen from the blood, potentially leading to ammonia buildup and serious health problems.
  • Crigler-Najjar Syndrome: A rare inherited disorder that affects the liver's ability to process bilirubin, leading to jaundice and potential brain damage if left untreated.
  • Fibroinflammatory Liver Diseases: A group of liver conditions characterized by inflammation and scarring (fibrosis) of liver tissue.
  • MELD-Na Score: Model for End-Stage Liver Disease with Sodium, a scoring system used to assess the severity of chronic liver disease and prioritize patients for liver transplantation.
  • Liver Transplantation: A surgical procedure where a diseased liver is replaced with a healthy liver from a donor.
  • Hepatic Encephalopathy: A decline in brain function that occurs as a result of severe liver disease, potentially causing confusion, altered level of consciousness, and coma.
  • Cirrhosis: A late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcoholism.

References

  1. http://clinicaltrials.eu/trial/long-term-safety-study-of-hepastem-for-patients-with-urea-cycle-disorders-crigler-najjar-syndrome-and-fibroinflammatory-liver-diseases/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-hepastem-for-patients-with-acute-on-chronic-liver-failure-aclf/